Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.70 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5105839 | 0.99 | MAPK14 (0.69) | MAPK14HSPB1CYP2C9MAPK11ROCK2 | |
| SCHEMBL6575551 | 0.93 | MAPK14 (0.71) | MAPK14HSPB1CYP2C9MAPK11ROCK2 | |
| SCHEMBL5102827 | 0.92 | MAPK14 (0.69) | MAPK14HSPB1CYP2C9MAPK11 | |
| SCHEMBL5098756 | 0.92 | MAPK14 (0.71) | MAPK14HSPB1CYP2C9MAPK11 | |
| SCHEMBL5106113 | 0.91 | MAPK14 (0.70) | MAPK14HSPB1CYP2C9MAPK11 | |
| SCHEMBL5102782 | 0.84 | MAPK14 (0.80) | MAPK14HSPB1CYP2C9MAPK11 | |
| SCHEMBL5098516 | 0.84 | MAPK14 (0.73) | MAPK14HSPB1CYP2C9MAPK11 | |
| SCHEMBL6676071 | 0.82 | MAPK14 (1.00) | MAPK14HSPB1CYP2C9MAPK11ROCK2 | |
| SCHEMBL5105259 | 0.81 | MAPK14 (0.59) | MAPK14CYP2C9CHRM3 | |
| SCHEMBL5102767 | 0.80 | DDR2 (0.66) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396843-B2 | 5′-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-08 | — | — | US | disclosed |
| US-20050038014-A1 | 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038014-A1 | 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | MAPK1, MAP4K2, MAP3K1 | MAPK14 18/4885HSPB1 2049/4885CYP2C9 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.